CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Head and Neck Cancer Awareness Month: 2022 Immunotherapy Research Updates

    This April for Head and Neck Cancer Awareness Month, discover the new research, new treatments, and progress…

    April 3, 2022| CRI Staff
  • Dr. Nabil F. Saba Answers Questions About Head and Neck Cancer and Immunotherapy After the 2021 CRI Virtual Immunotherapy Patient Summit

    Dr. Nabil F. Saba, of Winship Cancer Institute at Emory University, answers questions about immunotherapy for head…

    December 10, 2021| CRI Staff
  • Head and Neck Cancer Awareness Month: 2021 Immunotherapy Research Updates

    This April for Head and Neck Cancer Awareness Month, we look at new research, new treatments, and…

    April 7, 2021| CRI Staff
  • Head and Neck Cancer Awareness Month: 2020 Immunotherapy Research Update

    HPV’s connection to head and neck cancer, treatment options, side effects, and how we’re working toward a…

    April 14, 2020| CRI Staff
  • FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer

    New hope now exists for patients with advanced head and neck cancer.

    August 8, 2016| Alexandra Mulvey
  • ASCO 2016 Update: Immunotherapy’s Impact in Head & Neck Cancers

    Immunotherapy approaches provide improvements for patients with head and neck cancer.

    June 16, 2016| Arthur N. Brodsky, PhD
  • #AACR16 Update: New Hope for Patients with Rare Skin Cancer, Head & Neck Cancer

    Anti-PD-1 blockade and two other types of immunotherapy effective in treating multiple tumor types.

    April 20, 2016| Brian Brewer

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute

Group of three cancer survivors

Your support saves lives

Double Your Impact Today

On #Immune2Cancer Day, your gift matched up to $50,000

Photo of Cancer Survivors: Brendan Connors, Karen Peterson, and Tom Vibert